On-Site Magazine

Construction starts on new $245M biotech manufacturing facility in Quebec City

By On-Site Staff   


QUEBEC CITY—Work is underway on a new $245 million biotech complex in Quebec’s capital.

Medicago, a vaccine maker, officially broke ground on the site in Quebec City’s Estimauville Innovation Area Sept. 18.

The new 44,000 metres-square (approximately 475,000 sq. ft.) complex will house the company’s headquarters as well as production and research and development facilities. SNC-Lavalin provided design services for the site under a $12.5 million contract.

“This new complex will allow us to continue to revolutionize the traditional way of developing and producing vaccines and treatments,” Bruce Clark, Medicago’s president, said in a statement. “It will also give our teams an increased capacity to find new ways to treat a wide range of infectious diseases around the world.”


The biotech firm is based in Quebec City, though it’s a subsidiary of Japan’s Mitsubishi Tanabe Pharma following a $357 million 2013 acquisition. It develops and produces plant-based vaccines—a different approach than traditional biotech companies.

Construction on the new facility is scheduled to be complete by winter 2021.


Stories continue below

Print this page

on your radar Sponsored

Related Stories